biote earnings release, August 5, 2026

biote Corp. (BTMD) · Form 8-K, Item 2.02 · Filed · SEC filing

Biote Reports Second Quarter 2026 Financial Results

Continued progress in advancing strategic initiatives

Updates full-year outlook

Second Quarter 2026 Financial Highlights

• Revenue of $44.2 million

• Gross profit margin of 65.4%

• Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025

• Adjusted EBITDA¹ of $5.6 million and Adjusted EBITDA margin¹ of 12.6%

IRVING, TX–(BUSINESS WIRE)–August 5, 2026– Biote

(NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the second quarter ended June 30, 2026.

“Over the past year Biote has achieved meaningful progress in advancing our strategic initiatives, driving fundamental improvements that we believe position the Company to achieve sustainable procedure revenue growth,” said Bob Peterson, Biote’s interim Chief Executive Officer. “While not yet evident in our financial results, these foundational improvements have strengthened the core of our business and enhanced our resiliency, which we expect will drive improved financial performance in the second half.”

Mr. Peterson continued, “Our second quarter results primarily reflect continued impacts from the voluntary product recall, which affected revenue and margin. Underpinned by our leadership position and continued innovation, we remain focused on driving growth.”

2026 Second Quarter Financial Review

(All financial result comparisons made are against the prior-year period unless otherwise noted)

Total revenue was $44.2 million, a decrease of 9.5% from $48.9 million. Procedure revenue declined 13.9% to $30.3 million, and was impacted by the voluntary recall initiated in January 2026 of certain hormone pellets shipped by Asteria Health. Dietary supplements revenue grew 5.7% to $11.4 million.

Gross profit margin was 65.4%, as compared to 71.6%, as a result of impacts from the voluntary recall, which included the sourcing of replacement products from our third-party pellet suppliers at higher costs and reduced manufacturing efficiencies at Asteria Health.

_____________________________¹

Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP financial measures. Please see “Discussion of non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measure.

Operating income (loss) declined to a loss of $(3.5) million, from income of $10.8 million. Operating income (loss) decreased due to lower revenue and gross profit, as well as higher operating expenses.

Net loss was $(7.4) million and diluted loss per share attributable to biote Corp. stockholders was $(0.23), as compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10. Net income (loss) included a loss of $(0.8) million and $(1.8) million for the second quarter of 2026 and 2025, respectively, due to changes in the fair value of the earnout liabilities.

Adjusted EBITDA of $5.6 million decreased from $15.2 million and Adjusted EBITDA margin decreased to 12.6% from 31.1%. Both Adjusted EBITDA and Adjusted EBITDA margin decreased due to lower revenue, reduced gross profit and higher operating expenses.

Summary and 2026 Financial Outlook

Mr. Peterson concluded, “Our strategic initiatives program continues to guide the Company, and we are confident the foundational work completed over the past year has strengthened our business. As we enter the second half of 2026, we are moving into the next phase of our strategic roadmap, which is designed to drive deeper operational improvements that restore growth and improve the consistency of our financial performance. Key areas of focus include enhancing the practitioner experience; accelerating sales productivity; and driving growth across our network.

In terms of our 2026 outlook, we expect procedure revenue to show sequential improvement in both the third and fourth quarters, benefiting from a return to normalized inventory levels at Asteria Health. However, the impacts from the voluntary product recall earlier in the year have delayed our expected return to year-over-year procedure revenue growth. As a result, we are revising our full

‑ year financial outlook to reflect our first half performance and our current expectations for the remainder of the year. We remain focused on executing our strategy with discipline and continuing to advance the long

‑ term fundamentals of the business.”

• Procedure revenue is expected to improve sequentially in both the third and fourth quarters, versus prior guidance that anticipated a return to year-over-year growth in the second half. However, year-over-year procedure revenue in these periods is still expected to be negative due to the first-half disruption of the voluntary recall affecting near-term performance.

• 2026 Dietary supplements revenue is expected to grow at a mid to high single digit rate from 2025, unchanged from prior guidance.

_____________________________²

Please see “Forward-Looking Non-GAAP Financial Measures" below for additional information about forward-looking Adjusted EBITDA.

Conference Call:

Biote management will host a conference call to review these results and provide a business update beginning at 5:00 p.m. ET on Wednesday, August 5, 2026. To access the conference call by telephone, please dial (646) 307-1963 (U.S toll-free) or (800) 715-9871 (International) and reference conference ID:... (truncated) ir.biote.com, shortly after the event concludes.

Discussion of Non-GAAP Financial Measures

To provide investors with additional information regarding our financial results, Biote has disclosed Adjusted EBITDA, a non-GAAP financial measure that it calculates as net income (loss) before interest, taxes and depreciation and amortization, further adjusted to exclude stock-based compensation, litigation expenses, legal settlements, inventory fair value write-up, transaction-related expenses, restructuring-related expenses, certain other expenses, merger and acquisition expenses, fair value adjustments to certain equity instruments classified as liabilities and other expenses. Below we have provided a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure.

We present Adjusted EBITDA and Adjusted EBITDA margin because it is a key measure used by our management to evaluate our operating performance, generate future operating plans and determine payments under compensation programs. Accordingly, we believe that Adjusted EBITDA and Adjusted EBITDA margin provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management.

Adjusted EBITDA and Adjusted EBITDA margin have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are as follows:

• Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA and Adjusted EBITDA margin do not reflect cash capital expenditure requirements for such replacements of our assets;

• Adjusted EBITDA and Adjusted EBITDA margin do not reflect changes in, or cash requirements for, our working capital needs; and

• Adjusted EBITDA and Adjusted EBITDA margin do not reflect tax payments that may represent a reduction in cash available to us.

In addition, Adjusted EBITDA and Adjusted EBITDA margin are subject to inherent limitations as it reflects the exercise of judgment by Biote’s management about which expenses are excluded or included. A reconciliation is provided in the financial statement tables included below in this press release for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Because of these limitations, you should consider Adjusted EBITDA and Adjusted EBITDA margin alongside other financial performance measures, including net income (loss) and our other GAAP results.

Forward-Looking Non-GAAP Financial Measures

The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable GAAP financial measures because it could not do so without unreasonable effort due to the unavailability of certain information needed to calculate reconciling items. For example, the Company has not included a reconciliation of projected Adjusted EBITDA to GAAP net income (loss), which is the most directly comparable GAAP measure, for the periods presented in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K. The Company’s projected Adjusted EBITDA excludes certain items that are inherently uncertain and difficult to predict including, but not limited to, share-based compensation expense, income taxes, due diligence expenses and legal expenses. Due to the variability, complexity and limited visibility of the adjusting items that would be excluded from projected Adjusted EBITDA in future periods, management does not forecast them for internal use and therefore cannot create a quantitative projected Adjusted EBITDA to GAAP net income (loss) reconciliation for the periods presented without unreasonable efforts. A quantitative reconciliation of projected Adjusted EBITDA to GAAP net income (loss) for the periods presented would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors. From a qualitative perspective, it is anticipated that the differences between projected Adjusted EBITDA to GAAP net income (loss) for the periods presented will consist of items similar to those described in the financial tables later in this release, including, for example and without limitation, share-based compensation expense, income taxes, due diligence expenses and legal expenses. The timing and amount of any of these excluded items could significantly impact the Company’s GAAP net income (loss) for a particular period. When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis.

About Biote

Biote advances the healthspan of our Practitioners’ patients by providing innovative hormone optimization and healthy aging solutions. Through our network of Biote certified providers, we collaborate with leading clinicians to restore vitality and promote vibrant aging.

Financial statements

Income Statement

Three Months Ended June 30, — Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (In Thousands, except share and per share amounts) (Unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue:Product revenue43,38147,65787,27694,682
Revenue:Service revenue8511,2061,8913,173
Revenue:Total revenue44,23248,86389,16797,855
Cost of revenueCost of products14,30112,81127,04624,465
Cost of revenueCost of services1,0131,0642,2502,020
Cost of revenue15,31413,87529,29626,485
Cost of revenueSelling, general and administrative32,42624,22360,21350,915
Cost of revenueIncome (loss) from operations-3,50810,765-34220,455
Other income (expense), net:Interest expense, net-2,183-2,852-4,155-5,757
Other income (expense), net:Loss on extinguishment of debt-648-648
Other income (expense), net:Gain (loss) from change in fair value of earnout liabilities-787-1,8321,3628,856
Other income (expense), net:Other income (expense), net-6-6-11-24
Other income (expense), net:Total other income (expense), net-3,624-4,690-3,4523,075
Other income (expense), net:Income (loss) before provision for income taxes-7,1326,075-3,79423,530
Other income (expense), net:Income tax expense2962,1509583,766
Other income (expense), net:Net income (loss)-7,4283,925-4,75219,764
Other income (expense), net:Less: Net income (loss) attributable to noncontrolling interest-865740-4662,861
Other income (expense), net:Net income (loss) attributable to biote Corp. stockholders-6,5633,185-4,28616,903
Other comprehensive income:Foreign currency translation adjustments2945
Other comprehensive income:Other comprehensive income2945
Other comprehensive income:Comprehensive income (loss)-7,4263,934-4,74819,769
Net income (loss) per common shareBasic-0.230.1-0.140.54
Net income (loss) per common shareDiluted-0.230.1-0.140.46
Weighted average common shares outstandingBasic28,626,13631,625,48529,630,66531,556,017
Weighted average common shares outstandingDiluted28,626,13631,743,16229,630,66536,959,274

Income Statement

Three Months Ended (in thousands)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Net income (loss)-7,4283,925-4,75219,764
Interest expense, net(1)2,1832,8524,1555,757
Income tax expense2962,1509583,766
Depreciation and amortization(2)9639101,9431,767
Share-based compensation expense(3)1,9702,1863,7284,313
Litigation expenses-former owner(4)822232
Litigation-other(5)83427785892
Legal settlement and related expenses(6)5,065-2625,590-226
Restructuring-related expenses(7)555555
Other expenses(8)9575172,444852
Merger and acquisition expenses(9)37147110
Loss on extinguishment of debt(10)648648
Loss (gain) from change in fair value of earnout liabilities7871,832-1,362-8,856
Adjusted EBITDA5,56115,17414,28628,926
Total revenue44,23248,86389,16797,855
Net income (loss) margin(11)-16.8%8-5.3%20.2
Adjusted EBITDA margin(12)12.6%31.116.0%29.6

Balance Sheet

December 31, — Condensed Consolidated Balance Sheets (In Thousands) (Unaudited) (in thousands)

June 30, – 2026December 31, – 2025
Current assets:Cash and cash equivalents11,16824,123
Current assets:Accounts receivable, net7,8106,868
Current assets:Inventory, net18,33119,064
Current assets:Other current assets5,7314,615
Current assets:Total current assets43,04054,670
Current assets:Property and equipment, net12,84710,753
Current assets:Capitalized software, net4,8974,525
Current assets:Goodwill5,8335,833
Current assets:Intangible assets, net3,6494,266
Current assets:Operating lease right-of-use assets6,8462,701
Current assets:Deferred tax assets, net24,51524,793
Current assets:Other non-current assets7272
Current assets:Total assets101,699107,613
Current liabilities:Accounts payable6,5766,826
Current liabilities:Accrued expenses14,3219,806
Current liabilities:Term loan, current3,1256,250
Current liabilities:Deferred revenue, current2,6233,017
Current liabilities:Earnout liabilities, current2,750
Current liabilities:Operating lease liabilities, current705592
Current liabilities:Share repurchase liabilities18,500
Current liabilities:Total current liabilities30,10044,991
Current liabilities:Term loan, net of current portion118,37795,782
Current liabilities:Revolving loans5,000
Current liabilities:Deferred revenue, net of current portion7911,097
Current liabilities:Operating lease liabilities, net of current portion6,4332,298
Current liabilities:Other non-current liability344
Current liabilities:TRA liability4,1904,386
Current liabilities:Earnout liabilities4,112
Current liabilities:Total liabilities159,891158,010
Stockholders’ DeficitClass A common stock33
Stockholders’ DeficitClass V voting stock11
Stockholders’ DeficitAccumulated deficit-50,941-49,549
Stockholders’ DeficitAccumulated other comprehensive loss-25-29
Stockholders’ DeficitTreasury stock, at cost-14,828-8,965
Stockholders’ Deficitbiote Corp.’s stockholders’ deficit-65,790-58,539

Cash Flow

Six Months Ended June 30, — Condensed Consolidated Statements of Cash Flows (In Thousands) (Unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating ActivitiesNet income (loss)-4,75219,764
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Depreciation and amortization1,9431,767
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Bad debt (recovery) expense-771962
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Amortization of debt issuance costs378412
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Provision for (recovery of) obsolete inventory-1,3881,100
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Non-cash lease expense340268
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Non-cash interest on share repurchase liability1,986
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Share-based compensation expense3,7284,313
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Gain from change in fair value of earnout liabilities-1,362-8,856
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Loss on extinguishment of debt648
Adjustments to reconcile net income (loss) to net cash provided by operating activities:Deferred income taxes3401,285
Changes in operating assets and liabilities:Accounts receivable-171-2,406
Changes in operating assets and liabilities:Inventory2,1211,613
Changes in operating assets and liabilities:Other assets-1,116-2,387
Changes in operating assets and liabilities:Accounts payable-250-1,950
Changes in operating assets and liabilities:Deferred revenue-700-60
Changes in operating assets and liabilities:Accrued expenses4,171-3,910
Changes in operating assets and liabilities:Payments pursuant to TRA-196-93
Changes in operating assets and liabilities:Operating lease liabilities-237-255
Changes in operating assets and liabilities:Net cash provided by operating activities2,72613,553
Investing ActivitiesPurchases of property and equipment-2,919-3,439
Investing ActivitiesPurchases of capitalized software-873-371
Investing ActivitiesNet cash used in investing activities-3,792-3,810
Financing ActivitiesRepurchases of Class A common stock-5,863
Financing ActivitiesBorrowings on revolving loans12,500
Financing ActivitiesRepayments on revolving loans-17,500
Financing ActivitiesPrincipal repayments on term loan-1,563-3,125
Financing ActivitiesBorrowings on term loan125,000
Financing ActivitiesExtinguishment of debt-101,562
Financing ActivitiesDebt issuance costs-3,431
Financing ActivitiesPayments on repurchase liability-18,500-25,081
Financing ActivitiesProceeds from exercise of stock options226
Financing ActivitiesIssuance of stock under purchase plan4772
Financing ActivitiesDistributions-1,021-1,581
Financing ActivitiesNet cash used in financing activities-11,893-29,489
Financing ActivitiesEffect of exchange rate changes on cash and cash equivalents45
Financing ActivitiesNet decrease in cash and cash equivalents-12,955-19,741
Financing ActivitiesCash and cash equivalents at beginning of period24,12339,342
Financing ActivitiesCash and cash equivalents at end of period11,16819,601
Supplemental Disclosure of Cash Flow InformationCash paid for interest2,7744,022
Supplemental Disclosure of Cash Flow InformationCash paid for income taxes1,7262,508
Full release

Forward-Looking Statements... (truncated)risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: our investment in our sales and technology capabilities and its anticipated benefits on our business; anticipated benefits and successful execution of our organizational restructuring; the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our ability and the ability of certain third parties to effectively support the manufacturing of bio-identical hormones for prescribers; including the impact of the voluntary product recall of certain hormone pellets and our continued reliance on third-party pellet suppliers; our and our customers’ sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; changes to international tariffs, U.S. trade policy or similar government actions; geopolitical tensions; the inability to profitably expand in existing markets and into new markets; our ability to achieve the financial guidance provided in this press release or the possibility that we may need to further revise such guidance; and the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including the impact of hurricane and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the “Risk Factors” section of Biote’s Annual Report on Form

10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2026, as supplemented by Biote's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.

Financial Tables

Biote Corp.

Condensed Consolidated Balance Sheets (In Thousands) (Unaudited)

Biote Corp.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (In Thousands, except share and per share amounts) (Unaudited)

Biote Corp.

Condensed Consolidated Statements of Cash Flows (In Thousands) (Unaudited)

Biote Corp.

Reconciliation of Adjusted EBITDA to Net Income (Loss) (Unaudited)

The following table presents a reconciliation of net income (loss) to Adjusted EBITDA, as well as the calculation of net income (loss) margin and Adjusted EBITDA margin, for each of the periods indicated.

(1)

Represents cash and non-cash interest on our debt obligations, commitment fees on the unused portion of our Revolving Loans, net of interest income earned on our money market account. For the three and six months ended June 30, 2025, interest expense, net included $0.9 million and $2.0 million of accreted interest related to the share repurchase liability. There was no accreted interest for the three and six months ended June 30, 2026.

(2)

Represents depreciation expense on property and equipment, amortization expense on capitalized software and amortization expense on purchased intangible assets. Depreciation expense of $0.2 million and $0.06 million for the three months ended June 30, 2026 and 2025, respectively, and $0.4 million and $0.07 million for the six months ended June 30, 2026 and 2025, respectively, was included in cost of products.

(3)

Represents employee compensation expense associated with equity-based stock awards. This includes expense associated with equity incentive instruments including phantom stock awards, stock options and restricted stock units.

(4)

Represents legal expenses to defend the Company against claims asserted by the Company’s former owner.

(5)

Represents litigation expenses other than those incurred in connection with claims asserted by the Company’s former owner that are not related to the Company’s ongoing business.

(6)

Represents legal expenses incurred in connection with litigation settlement gains or losses.

(7)

Represents restructuring costs incurred during the three and six months ended June 30, 2025 related to a workforce reduction primarily within our commercial organization. No such restructuring costs were incurred during the three and six months ended June 30, 2026.

(8)... (truncated) than $0.01 million and strategic consulting and legal expenses related to the CEO transition of $0.3 million for the six months ended June 30, 2025.

(9)

Represents legal fees totaling $0.04 million and $0.1 million incurred during the three and six months ended June 30, 2026 related to strategic opportunities to expand the business. For the six months ended June 30, 2025 this amount represents legal fees and professional fees totaling $0.1 million incurred to finalize the purchase price allocation of Asteria Health and for other strategic opportunities to expand the business.

(10)

Represents the remaining unamortized portion of the debt issuance costs related to the Credit Agreement written off upon executing the Amended Credit Agreement with Truist Bank.

(11)

Net income margin is defined as net income divided by total revenue.

(12)

Adjusted EBITDA margin is defined as adjusted EBITDA divided by total revenue.

Investor Relations:

Eric Prouty

AdvisIRy Partners eric.prouty@advisiry.com

Media:

Press@biote.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.